Related Experiment Video
Updated: May 5, 2026

Assessment of the Metabolic Profile of Primary Leukemia Cells
Published on: November 21, 2018
Clinico-Metabolic Profiling Unraveled Key Metabolic Alterations Underlying the Pathophysiology of Chronic Myeloid
Surbhi Gupta1, Nitu Nigam1, Shailendra Prasad Verma1
1King George's Medical University (KGMU), Lucknow 226003, UP, India.
Abstract:
Chronic myeloid leukemia (CML) is a myeloproliferative neoplasm. Despite the success of tyrosine kinase inhibitors, therapeutic resistance and disease progression remain significant challenges. This highlights the need for novel biomarkers to facilitate early diagnosis, deepen our understanding of the disease, and pave the way for new therapeutic approaches. This study analyzed serum metabolic profiles of 30 newly diagnosed treatment-naive CML patients and 20 age- and sex-matched healthy controls using 1H nuclear magnetic resonance (NMR) spectroscopy, followed by multivariate and univariate statistical approaches. Diagnostic performance was evaluated by receiver operating characteristic (ROC) curve analysis. Thirty-eight metabolites were identified, and multivariate analysis revealed significant metabolic disparity between CML and control subjects with substantial alterations in amino acid and energy metabolism. Key eight metabolites, including histidine, alanine, valine, glutamine, tyrosine, serine, glucose, and isoleucine, demonstrated consistent downregulation in CML, reflecting enhanced cellular uptake and metabolic rewiring characteristic of leukemic proliferation. Depletion of branched-chain amino acids and increased reliance on glutamine and glycolytic intermediates highlight vulnerabilities that may be exploited for therapeutic intervention. ROC analysis demonstrated promising discriminatory ability of these metabolites in this cohort, with several achieving an area under the ROC curve (AUROC) > 0.90, suggesting their potential as biomarkers in this cohort their utility . Serum metabolomics reveals a distinct CML signature marked by enhanced bioenergetic and biosynthetic demands, immune evasion, and drug resistance mechanisms. These findings underscore the potential of serum metabolic profiles as noninvasive biomarkers at the exploratory discovery stage, while also providing preliminary pathophysiological insights that may guide future studies on metabolism-targeted therapeutic strategies.
Insights
Serum metabolomics reveals distinct metabolic profiles in chronic myeloid leukemia (CML). Key amino acids and glucose are downregulated in CML patients, suggesting potential as novel biomarkers for early diagnosis and targeted therapies.
Area of Science:
- Biochemistry
- Oncology
- Metabolomics
Background:
- Chronic myeloid leukemia (CML) is a myeloproliferative neoplasm.
- Tyrosine kinase inhibitors (TKIs) are effective but face challenges with resistance and progression.
- Novel biomarkers are needed for early diagnosis, understanding CML, and developing new therapies.
Purpose of the Study:
- To analyze serum metabolic profiles in newly diagnosed, treatment-naive CML patients compared to healthy controls.
- To identify potential noninvasive biomarkers for CML diagnosis and therapeutic strategies.
Main Methods:
- Serum samples from 30 CML patients and 20 healthy controls were analyzed using 1H nuclear magnetic resonance (NMR) spectroscopy.
- Multivariate and univariate statistical analyses were employed to identify metabolic differences.
- Receiver operating characteristic (ROC) curve analysis was used to evaluate diagnostic performance.
Main Results:
- Significant metabolic disparities were observed between CML patients and controls, particularly in amino acid and energy metabolism.
- Eight key metabolites (histidine, alanine, valine, glutamine, tyrosine, serine, glucose, isoleucine) were consistently downregulated in CML.
- These downregulated metabolites reflect enhanced cellular uptake and metabolic rewiring in leukemic proliferation.
- ROC analysis showed promising discriminatory ability, with several metabolites achieving an area under the ROC curve (AUROC) > 0.90.
Conclusions:
- Serum metabolomics reveals a distinct CML signature associated with increased bioenergetic/biosynthetic demands and immune evasion.
- Downregulated amino acids and altered glucose metabolism highlight potential therapeutic vulnerabilities.
- Serum metabolic profiles show promise as noninvasive biomarkers for CML, aiding future metabolism-targeted therapies.
More Related Videos
13:21Comprehensive DNA Methylation Analysis Using a Methyl-CpG-binding Domain Capture-based Method in Chronic Lymphocytic Leukemia Patients
Published on: June 16, 2017
10:18From a 2DE-Gel Spot to Protein Function: Lesson Learned From HS1 in Chronic Lymphocytic Leukemia
Published on: October 19, 2014